Additionally, we acknowledge the importance of incorporating other tools to validate the AD model, such as assessing skin barrier integrity through TEWL (transepidermal water loss) measurements or evaluating barrier proteins like filaggrin, loricrin, or claudin-1. Here, CLDN1 is linked to Alzheimer disease.